ATE300952T1 - Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem - Google Patents

Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem

Info

Publication number
ATE300952T1
ATE300952T1 AT00984018T AT00984018T ATE300952T1 AT E300952 T1 ATE300952 T1 AT E300952T1 AT 00984018 T AT00984018 T AT 00984018T AT 00984018 T AT00984018 T AT 00984018T AT E300952 T1 ATE300952 T1 AT E300952T1
Authority
AT
Austria
Prior art keywords
central nervous
nervous system
administration
active ingredients
disorders
Prior art date
Application number
AT00984018T
Other languages
English (en)
Inventor
William H Ii Frey
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE300952T1 publication Critical patent/ATE300952T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00984018T 1999-12-09 2000-12-08 Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem ATE300952T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20070899P 1999-12-09 1999-12-09
PCT/US2000/033220 WO2001041782A2 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system

Publications (1)

Publication Number Publication Date
ATE300952T1 true ATE300952T1 (de) 2005-08-15

Family

ID=22742853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984018T ATE300952T1 (de) 1999-12-09 2000-12-08 Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem

Country Status (10)

Country Link
US (3) US20010043915A1 (de)
EP (1) EP1237567B1 (de)
JP (1) JP2003516360A (de)
AT (1) ATE300952T1 (de)
AU (1) AU783208B2 (de)
CA (1) CA2393688A1 (de)
DE (1) DE60021760T2 (de)
IL (1) IL150109A0 (de)
NO (1) NO20022731L (de)
WO (1) WO2001041782A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
US6589591B1 (en) * 2001-07-10 2003-07-08 Baylor College Of Medicine Method for treating medical devices using glycerol and an antimicrobial agent
AU2002367394A1 (en) * 2001-12-28 2003-07-24 Genzyme Corporation Bioresorbable foam packing device and use thereof
PT1471974E (pt) * 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
EP1487474A4 (de) * 2002-02-25 2006-11-29 Chiron Corp Intranasale verabreichung von mc4-r agonisten
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1599474B1 (de) 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclische oligomere Verbindungen zur DNS-Erkennung
CA2516990A1 (en) * 2003-03-19 2004-09-30 Ares Trading S.A. Treatment of alzheimer's disease
FR2864901B1 (fr) * 2004-01-09 2007-10-05 Philippe Perovitch Composition pour le traitement au contact des hyposialies, incluant de la pilocarpine et a effets multiples
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
AU2005251786A1 (en) * 2004-06-07 2005-12-22 Nastech Pharmaceutical Company Inc. Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP1877434A2 (de) * 2005-05-04 2008-01-16 Nautilus Biotech Modifizierte interferon-gamma-polypeptide und verfahren zur anwendung modifizierter interferon-gamma-polypeptide
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP1915986A1 (de) * 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Wachstumsfaktorhaltige Lipidformulierungen
EP2152240A4 (de) * 2007-06-08 2012-05-09 Healthpartners Res Foundation Pharmazeutische zusammensetzungen und verfahren für verstärktes abzielen therapeutischer verbindungen auf das zentralnervensystem
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US8221358B2 (en) * 2007-11-20 2012-07-17 Warsaw Orthopedic, Inc. Devices and methods for delivering drug depots to a site beneath the skin
RU2357743C1 (ru) * 2008-02-01 2009-06-10 Аркадий Александрович Каспаров Средство для лечения, способ получения средства для лечения и способ лечения отека роговицы и других проявлений ранней буллезной кератопатии
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
EP2307036A4 (de) 2008-06-13 2012-08-08 Wisconsin Alumni Res Found Neues peptid-adjuvans für die grippeimpfung
EP2310030A4 (de) 2008-06-13 2013-08-14 Wisconsin Alumni Res Found Neue antivirale peptide gegen das influenzavirus
US20100106132A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising superior and inferior covers
US20100106136A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug delivery device with sliding cartridge
US9352137B2 (en) * 2008-10-29 2016-05-31 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
US20110263580A1 (en) * 2008-12-11 2011-10-27 Thomas Miller Method for treating alzheimer's disease and related conditions
US8440631B2 (en) * 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CA2756206C (en) 2009-03-27 2025-05-13 Academia Sinica METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST A VIRUS
WO2011011725A2 (en) 2009-07-24 2011-01-27 Schultz-Cherry Stacey L Use of toxoplasma and derived compositions to prevent or treat microbial infections
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2828884C (en) 2011-03-03 2021-04-27 Impel Neuropharma, Inc. Nasal drug delivery device
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
JP6645735B2 (ja) 2011-05-09 2020-02-14 インペル ニューロファーマ インコーポレイテッド 鼻薬送達用ノズル
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
EP4085899A1 (de) 2011-06-14 2022-11-09 Neurelis, Inc. Verabreichung von benzodiazepin
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
EP2822600A4 (de) 2012-03-09 2016-04-06 Univ Northeastern Verfahren zur abgabe von nucleinsäurenanopartikeln an das zentrale nervensystem zur behandlung von erkrankungen des zentralen nervensystems
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
US9033912B2 (en) 2012-03-28 2015-05-19 Warsaw Orthopedic, Inc. Drug delivery system
US20130280297A1 (en) 2012-04-11 2013-10-24 Lori Neal Use of toxoplasma gene products to prevent or treat microbial infections
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
US10537692B2 (en) 2013-04-28 2020-01-21 Impel Neuropharma, Inc. Medical unit dose container
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US9901684B2 (en) 2013-10-17 2018-02-27 Warsaw Orthopedic, Inc. Drug delivery device with retaining member
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
WO2015179415A1 (en) 2014-05-19 2015-11-26 Novartis Ag Methods of treating anorexia
USD809652S1 (en) 2014-07-25 2018-02-06 Warsaw Orthopedic, Inc. Drug delivery device
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
HUE070412T2 (hu) 2016-04-12 2025-06-28 Tonix Pharma Ltd Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
US10549081B2 (en) 2016-06-23 2020-02-04 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
CN106620656A (zh) * 2017-03-03 2017-05-10 上海唯科生物制药有限公司 一种肿瘤坏死因子舌下给药制剂及其制备方法
JP7284156B2 (ja) 2017-09-19 2023-05-30 アドバクシス， インコーポレイテッド 細菌またはＬｉｓｔｅｒｉａ株の凍結乾燥のための組成物および方法
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2019241579A1 (en) 2018-06-13 2019-12-19 Wisconsin Alumni Research Foundation Toxoplasma gondii vaccine
CA3125430A1 (en) 2019-01-03 2020-07-09 Impel Neuropharma, Inc. Nasal drug delivery device
CN116096920A (zh) 2020-06-23 2023-05-09 科罗拉多大学董事会法人团体 用于诊断呼吸道病原体和预测covid-19相关结果的方法
WO2022215036A1 (en) 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
CN117580579A (zh) 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物
CN119212751A (zh) 2021-10-19 2024-12-27 奥拉基因公司 用于治疗包括脑震荡的创伤性脑损伤(tbi)的呼吸驱动鼻装置以及方法和方法
WO2026018213A1 (en) 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
SU1139444A1 (ru) 1982-12-15 1985-02-15 Iretskij Andrej N Способ введени нейротропных и гормональных препаратов
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
GB8918264D0 (en) * 1989-08-10 1989-09-20 Furnell David Rotary display unit
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5482706A (en) * 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
KR100304017B1 (ko) * 1992-06-22 2001-11-22 추후제출 글리신수용체길항물질및이의용도
JPH0741428A (ja) 1993-07-30 1995-02-10 Teijin Ltd ペプチド、蛋白質性薬物経鼻・経肺製剤
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5675942A (en) * 1995-08-28 1997-10-14 Crawford; Van Wall panel alignment device and spacer
CA2253971A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty.Ltd. Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
US6036949A (en) * 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AU2173400A (en) * 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis

Also Published As

Publication number Publication date
DE60021760D1 (de) 2005-09-08
IL150109A0 (en) 2002-12-01
CA2393688A1 (en) 2001-06-14
AU783208B2 (en) 2005-10-06
US6991785B2 (en) 2006-01-31
US20060159626A1 (en) 2006-07-20
DE60021760T2 (de) 2006-06-08
EP1237567A2 (de) 2002-09-11
US20010043915A1 (en) 2001-11-22
WO2001041782A3 (en) 2002-01-17
JP2003516360A (ja) 2003-05-13
AU2069801A (en) 2001-06-18
WO2001041782A2 (en) 2001-06-14
EP1237567B1 (de) 2005-08-03
US20020141971A1 (en) 2002-10-03
NO20022731D0 (no) 2002-06-07
NO20022731L (no) 2002-08-08

Similar Documents

Publication Publication Date Title
ATE300952T1 (de) Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
WO2005000215A3 (en) Methods for treating pain
Dafny et al. Interferon and the central nervous system
Dahl Imiquimod: a cytokine inducer
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
JP2003516360A5 (de)
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
PT858343E (pt) Terapia por infusao continua de uma dose baixa de citoquina
BR9814458A (pt) Composto, composição farmacêutica e método de tratamento de disfunções afetivas
NZ212632A (en) Tumor necrosis factor, its preparation and its use
DE69928563D1 (de) Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem
RU98115594A (ru) Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
AU2173400A (en) Method for administering agents to the central nervous system
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
ZA865735B (en) Pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
ATE320270T1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
STEHLE et al. Serum levels of tumor necrosis factor α in patients treated with granulocyte-macrophage colony-stimulating factor
Naveau et al. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment
DE60235955D1 (de) Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
ATE257727T1 (de) Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten
DE60023944D1 (de) Replikationsunfähige herpesvirus-vektoren
DE3875065D1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties